Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SAB Biotherapeutics, Inc. Director's Dealing 2021

Jan 14, 2021

34961_dirs_2021-01-14_f9620b10-4920-40a0-ad01-7bc81d67258d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Big Cypress Acquisition Corp. (BCYP)
CIK: 0001833214
Period of Report: 2021-01-14

Reporting Person: Katz Ilan (Director, 10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-01-14 Common Stock P 417200 $10.00 Acquired 3047825 Indirect

Footnotes

F1: The reported shares are included within the 417,200 private placement units of the issuer purchased by Big Cypress Holdings LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the issuer's initial public offering, and each such unit consists of one share of common stock of the issuer and one-half of one warrant of the issuer. The warrants included in the units will become exercisable, if at all, on the later of 30 days after the completion of the issuer's initial business combination and 12 months from the closing of the issuer' initial public offering. The securities are held directly by the Sponsor and indirectly by Samuel J. Reich and Ilan Katz as managers of the Sponsor.